乐观
$21.71
情景价格
$14.810
-0.110 (-0.74%)收盘时
Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling).
Mirion Technologies is currently not a strong buy due to its low RSI of 33.18 and a significant year-to-date decline of 37.85%. However, the stock has shown impressive annual revenue growth of 11.7% over the past two years, which suggests potential for recovery. The main risk is the high P/E ratio of 150.43, indicating that the stock may be overvalued at its current price of $14.81.
情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

Mirion Schedules Q3 2026 Financial Results Release and Conference Call

Mirion CFO Acquires 20,000 Shares of Stock

Mirion Technologies CFO's Stock Purchase Signals Bullish Outlook

Analysis of Promising Stocks Under $50

Latest Ratings and Outlook from Wall Street
Mirion Technologies, Inc. is a global provider of radiation detection, measurement, analysis, and monitoring solutions to the nuclear, medical, defense, and research end markets. The Company's segments include Medical, and Nuclear & Safety. The Medical segment includes products and services for radiation therapy, nuclear medicine and personal dosimetry. This segment’s principal product offering is in Radiation Therapy Quality Assurance, which includes solutions for calibrating and/or verifying imaging, treatment machine, patient treatment plan, and patient treatment accuracy. The Nuclear & Safety segment includes products and services focused on addressing critical radiation safety, measurement and analysis applications across nuclear energy, laboratories and research and other industrial markets such as defense. For nuclear power plants (NPPs), it sells products and services for use at any stage of their life (construction, operation, decommissioning and dismantling). It operates in the Industrials sector (MEASURING & CONTROLLING DEVICES, NEC industry).
Mirion Technologies is currently not a strong buy due to its low RSI of 33.18 and a significant year-to-date decline of 37.85%. However, the stock has shown impressive annual revenue growth of 11.7% over the past two years, which suggests potential for recovery. The main risk is the high P/E ratio of 150.43, indicating that the stock may be overvalued at its current price of $14.81.
暂无帖子
注册或登录后参与讨论本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。